FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:2705-2707 December 21, 2006 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article PubMed Citation

To the Editor: The intravesical administration of bacille Calmette–Guérin (BCG) vaccine for high-risk, non–muscle-invasive bladder cancer and carcinoma in situ is one of the most successful immunotherapies to date.¹ Studies in animals have shown that the generation of effector cells, called BCG-activated killer cells, depends on type 1 helper T (Th1)–type cytokines.² In humans, a high Th1-biased urinary cytokine profile after several weekly intravesical instillations of BCG correlates with a better clinical response.³

Statins have cholesterol-lowering properties and also immunomodulating actions. Several reports have indicated that statins can induce antiinflammatory type 2 helper T (Th2)–type cytokines (interleukin-4, interleukin-5, and interleukin-10) . . . [Full Text of this Article]

Related Letters:

Statins and the Effect of BCG on Bladder Cancer
Kamat A. M., Wu X., Orsola A., Cecchini L., Bellmunt J., Hoffmann P., Roumeguère T., van Velthoven R.
Extract | Full Text | PDF  
N Engl J Med 2007; 356:1276-1277, Mar 22, 2007. Correspondence

This article has been cited by other articles:

• Kamat, A. M., Wu, X., Orsola, A., Cecchini, L., Bellmunt, J., Hoffmann, P., Roumeguere, T., van Velthoven, R. (2007). Statins and the Effect of BCG on Bladder Cancer. NEJM 356: 1276-1277 [Full Text]